Kris Siemionow 0:04
I'm showing you a video which is very relevant. This is a video I took several years ago as a spine surgeon. And there are essentially multiple problems with the way spine surgery is performed today, in my opinion as a spine surgeon, the video first of all, does not show you anything about relevant anatomy, it's very difficult to understand what is going on. But most importantly, it actually destroys healthy tissue in order to access the pathology. So the bad news for you for sticking around so long today's all of us are going to develop spinal stenosis, just sign of aging. Of course, not all of us will end up in the operating room, but there are over 300,000 laminectomy cases performed in the US every year, both open and minimally invasive techniques are used. And yeah, that's a real picture from the operating room that's being performed, essentially every day. So open techniques, as you can imagine, are very destructive. And all current techniques result in a violation of healthy muscle tissue ligament, bone tendon, essentially resulting in prolonged hospital stays pain, pain and morbidity, etc. So there's currently really no technology available to treat a lumbar spinal stenosis from inside of the spinal canal. So how to approach the inside of the spinal canal without violating healthy tissue. Right. So that's the question, but you can do it via the sacral hiatus. And that's what you see here on this picture of a cadaveric sample. And I say sacral Hi, Ada are like companions, I think Hyena is the plural of sacred Ada CeQur. Hyatt are like opinions where everybody has one. So the good news is are essentially three morphological types. And all of these are amenable to access from a surgical perspective. So the approach is not really novel. It's used daily in anesthesiology and pain management. It's a very common procedure, both inpatient and outpatient. This technique has evolved over the years into what's called epidural Skippy, and that's what you see, on the top left image, you see a very lousy picture of the dura you see the disk and you see some kind of a blue probe there bottom X rays demonstrate that doctors actually do place endoscopes via the sacral hiatus and have been doing it actually since the 1990s. This is a very well described approach. You can see here an access trocar and endoscope that's being placed inside the spinal canal from this approach. The point I'm trying to make is we're not inventing a new approach. Although it's commonly performed, it has multiple limitations. And the list is long. First and foremost, it's very technically challenging, which is why adoption rates for this type of technology very low, you have limited control of the endoscope. It's highly dependent on surgeon dexterity. It's very difficult for the surgeon to understand where they are in relationship to the anatomy. Where am I? That's not a question a surgeon wants to be asking during a spinal procedure, very limited control of the instruments and limited instruments sets, challenging workflows, limited field of view, there's really no way to retract or protecting neural structures, radiation exposure to surgeons hunched over at the patient at the bedside and of course cost. So our solution is the semi autonomous platform for spinal decompression, which we feel should be deployed via the sacral hiatus approach. So you see the robot it's a very small device. And this is of course, a schematic targeting a three by six millimeter device that has two portals a primary portal, and a secondary instrument portal. You can pack a lot actually into small amount of real estate. As you can see suction laser irrigation light camera, flexible instrument portal and and em tracking system. So this is a schematic of how the robot looks deployed through that sacral hiatus. And here's how you can envision it accessing the ligamentum flavum, which is located just below the spine, this process. So we feel there are multiple advantages to this way of accessing, accessing spinal pathology. First and foremost, the surgeon gets to sit. So I don't know how familiar with spine surgery but the surgeon never sits, right. So it's a standing only a procedure which can take hours at a time. You're away from the operative field, meaning you don't suffer from a radiation exposure. The sacral hiatus approach is simple in a sense that it's once again used daily in the operating room. So we're not introducing any novel instruments or complexity there. The E M navigation allows the surgeon to have anatomical awareness. And one of the limitations today in spinal endoscopy is anatomy recognition. So you have a camera, it's showing you an image but what is that that I'm looking at? Right? So that's a very big limiting factor from adoption from a learning curve perspective. So we have to build a team of some as medical professionals that actually mark all the endoscopy images for us as far as relevant anatomy, so fat nerve disc ligamentum, etc bone. And then we feed that into the computer and we train our algorithms to recognize that life, endoscopy camera image video streams, which we feel have multiple advantages. So first of all, we offer multiclass tissue segmentation based on the camera feed. This is, of course, enabling type of technology, which we feel will flatten the learning curve, so reduce the stress factor for the doctor and understanding what the anatomy is. From a robotics perspective, main advantages of actually having a robot is that there's really less dexterity independent so the surgeon, dexterity does not play as much of a role. The software can stabilize the movements of the robot. There are built in safety features such as preventing the robot because we track where it is from the EM sensors preventing the robot from rapidly moving towards a nervous structure neural structure. The robot can be rigid when needed, and allows for debris removal because always the question is how do I remove what I need to remove and what's the channel and way of doing that? So this is quickly about our team. We have a very experienced team but myself and Christian have founded holo surgical before in 2015 companies acquired in 2020. We have reconstructed the team right now we have 10 people. We have filed our foundational patents. We have a second generation prototype of the robot, and we have our first generation AI algorithms that are currently working. So financial status and plan milestone this is a founder finance company. We anticipate our first cadaver lab in q3 of this year. We plan to be CE mark ready by fourth quarter of 2024. And we are raising money right now to meet these milestones. Thank you
Dr. Kris B. Siemionow, M.D., Ph.D. is the founder and principal of Siemionow Ventures (siemionow.com), a life-sciences and deep technology focused venture building and crossover fund investing in the most breakthrough ideas that will revolutionize healthcare.
Prior to starting SV, Dr. Siemionow was a board-certified spine surgeon and Tenured Associate Professor of Orthopaedics and Neurosurgery at the University of Illinois in Chicago.
As an entrepreneur Dr. Siemionow focuses on applying machine learning technologies to life-sciences, biotech, and medical devices.
Dr. Siemionow was the founder and CEO of HoloSurgical, a digital surgery company, which performed the first in man surgery with its augmented reality and artificial intelligence system on January 9th, 2019. The Company was acquired in October of 2020.
Dr. Siemionow was the founder of Inteneural Networks Inc, a company developing AI tools for brain MRI analytics. The company was acquired in December of 2021.
Dr. Siemionow is co-founder and director at Dystrogen Therapeutics, a clinical stage cell engineering company, which is developing chimeric cell therapies for musculoskeletal, neurologic, and blood disorders. www.dystrogen.com
Dr Siemionow is co-founder and director at Dystrogen Gene Therapies, which is developing an RNAi based approach for CAG repeat disorders like Huntington’s disease. www.dystrogene.com
Dr. Siemionow has published over 100 scientific articles focusing on digital surgery, artificial intelligence, cell therapy, and neurosurgery. He holds multiple patents for developing devices and technologies used in nerve regeneration, digital surgery, cardiology, spine surgery, cell therapy many of which have been commercialized. His PhD focused on studying the effects of inflammation on the central and peripheral nervous system.
Dr. Siemionow is co-founder of Global Spine Outreach. As part of Global Spine Outreach, Dr. Siemionow performed surgery in several European and Central American cities. Dr. Siemionow also participated in spine surgery missions to Uganda, East Africa, where he treated both children and adults suffering from spinal trauma, scoliosis, tumors, and infection.
Dr. Siemionow completed a residency in Orthopaedic Surgery at the Cleveland Clinic in Cleveland, Ohio and fellowship training in Adult Spine Surgery at Rush University Medical Center and a Pediatric Spine Fellowship at the Shriners Hospital for Children.
Dr. Kris B. Siemionow, M.D., Ph.D. is the founder and principal of Siemionow Ventures (siemionow.com), a life-sciences and deep technology focused venture building and crossover fund investing in the most breakthrough ideas that will revolutionize healthcare.
Prior to starting SV, Dr. Siemionow was a board-certified spine surgeon and Tenured Associate Professor of Orthopaedics and Neurosurgery at the University of Illinois in Chicago.
As an entrepreneur Dr. Siemionow focuses on applying machine learning technologies to life-sciences, biotech, and medical devices.
Dr. Siemionow was the founder and CEO of HoloSurgical, a digital surgery company, which performed the first in man surgery with its augmented reality and artificial intelligence system on January 9th, 2019. The Company was acquired in October of 2020.
Dr. Siemionow was the founder of Inteneural Networks Inc, a company developing AI tools for brain MRI analytics. The company was acquired in December of 2021.
Dr. Siemionow is co-founder and director at Dystrogen Therapeutics, a clinical stage cell engineering company, which is developing chimeric cell therapies for musculoskeletal, neurologic, and blood disorders. www.dystrogen.com
Dr Siemionow is co-founder and director at Dystrogen Gene Therapies, which is developing an RNAi based approach for CAG repeat disorders like Huntington’s disease. www.dystrogene.com
Dr. Siemionow has published over 100 scientific articles focusing on digital surgery, artificial intelligence, cell therapy, and neurosurgery. He holds multiple patents for developing devices and technologies used in nerve regeneration, digital surgery, cardiology, spine surgery, cell therapy many of which have been commercialized. His PhD focused on studying the effects of inflammation on the central and peripheral nervous system.
Dr. Siemionow is co-founder of Global Spine Outreach. As part of Global Spine Outreach, Dr. Siemionow performed surgery in several European and Central American cities. Dr. Siemionow also participated in spine surgery missions to Uganda, East Africa, where he treated both children and adults suffering from spinal trauma, scoliosis, tumors, and infection.
Dr. Siemionow completed a residency in Orthopaedic Surgery at the Cleveland Clinic in Cleveland, Ohio and fellowship training in Adult Spine Surgery at Rush University Medical Center and a Pediatric Spine Fellowship at the Shriners Hospital for Children.
Kris Siemionow 0:04
I'm showing you a video which is very relevant. This is a video I took several years ago as a spine surgeon. And there are essentially multiple problems with the way spine surgery is performed today, in my opinion as a spine surgeon, the video first of all, does not show you anything about relevant anatomy, it's very difficult to understand what is going on. But most importantly, it actually destroys healthy tissue in order to access the pathology. So the bad news for you for sticking around so long today's all of us are going to develop spinal stenosis, just sign of aging. Of course, not all of us will end up in the operating room, but there are over 300,000 laminectomy cases performed in the US every year, both open and minimally invasive techniques are used. And yeah, that's a real picture from the operating room that's being performed, essentially every day. So open techniques, as you can imagine, are very destructive. And all current techniques result in a violation of healthy muscle tissue ligament, bone tendon, essentially resulting in prolonged hospital stays pain, pain and morbidity, etc. So there's currently really no technology available to treat a lumbar spinal stenosis from inside of the spinal canal. So how to approach the inside of the spinal canal without violating healthy tissue. Right. So that's the question, but you can do it via the sacral hiatus. And that's what you see here on this picture of a cadaveric sample. And I say sacral Hi, Ada are like companions, I think Hyena is the plural of sacred Ada CeQur. Hyatt are like opinions where everybody has one. So the good news is are essentially three morphological types. And all of these are amenable to access from a surgical perspective. So the approach is not really novel. It's used daily in anesthesiology and pain management. It's a very common procedure, both inpatient and outpatient. This technique has evolved over the years into what's called epidural Skippy, and that's what you see, on the top left image, you see a very lousy picture of the dura you see the disk and you see some kind of a blue probe there bottom X rays demonstrate that doctors actually do place endoscopes via the sacral hiatus and have been doing it actually since the 1990s. This is a very well described approach. You can see here an access trocar and endoscope that's being placed inside the spinal canal from this approach. The point I'm trying to make is we're not inventing a new approach. Although it's commonly performed, it has multiple limitations. And the list is long. First and foremost, it's very technically challenging, which is why adoption rates for this type of technology very low, you have limited control of the endoscope. It's highly dependent on surgeon dexterity. It's very difficult for the surgeon to understand where they are in relationship to the anatomy. Where am I? That's not a question a surgeon wants to be asking during a spinal procedure, very limited control of the instruments and limited instruments sets, challenging workflows, limited field of view, there's really no way to retract or protecting neural structures, radiation exposure to surgeons hunched over at the patient at the bedside and of course cost. So our solution is the semi autonomous platform for spinal decompression, which we feel should be deployed via the sacral hiatus approach. So you see the robot it's a very small device. And this is of course, a schematic targeting a three by six millimeter device that has two portals a primary portal, and a secondary instrument portal. You can pack a lot actually into small amount of real estate. As you can see suction laser irrigation light camera, flexible instrument portal and and em tracking system. So this is a schematic of how the robot looks deployed through that sacral hiatus. And here's how you can envision it accessing the ligamentum flavum, which is located just below the spine, this process. So we feel there are multiple advantages to this way of accessing, accessing spinal pathology. First and foremost, the surgeon gets to sit. So I don't know how familiar with spine surgery but the surgeon never sits, right. So it's a standing only a procedure which can take hours at a time. You're away from the operative field, meaning you don't suffer from a radiation exposure. The sacral hiatus approach is simple in a sense that it's once again used daily in the operating room. So we're not introducing any novel instruments or complexity there. The E M navigation allows the surgeon to have anatomical awareness. And one of the limitations today in spinal endoscopy is anatomy recognition. So you have a camera, it's showing you an image but what is that that I'm looking at? Right? So that's a very big limiting factor from adoption from a learning curve perspective. So we have to build a team of some as medical professionals that actually mark all the endoscopy images for us as far as relevant anatomy, so fat nerve disc ligamentum, etc bone. And then we feed that into the computer and we train our algorithms to recognize that life, endoscopy camera image video streams, which we feel have multiple advantages. So first of all, we offer multiclass tissue segmentation based on the camera feed. This is, of course, enabling type of technology, which we feel will flatten the learning curve, so reduce the stress factor for the doctor and understanding what the anatomy is. From a robotics perspective, main advantages of actually having a robot is that there's really less dexterity independent so the surgeon, dexterity does not play as much of a role. The software can stabilize the movements of the robot. There are built in safety features such as preventing the robot because we track where it is from the EM sensors preventing the robot from rapidly moving towards a nervous structure neural structure. The robot can be rigid when needed, and allows for debris removal because always the question is how do I remove what I need to remove and what's the channel and way of doing that? So this is quickly about our team. We have a very experienced team but myself and Christian have founded holo surgical before in 2015 companies acquired in 2020. We have reconstructed the team right now we have 10 people. We have filed our foundational patents. We have a second generation prototype of the robot, and we have our first generation AI algorithms that are currently working. So financial status and plan milestone this is a founder finance company. We anticipate our first cadaver lab in q3 of this year. We plan to be CE mark ready by fourth quarter of 2024. And we are raising money right now to meet these milestones. Thank you
Market Intelligence
Schedule an exploratory call
Request Info17011 Beach Blvd, Suite 500 Huntington Beach, CA 92647
714-847-3540© 2024 Life Science Intelligence, Inc., All Rights Reserved. | Privacy Policy